Adebisi Abiodun Adeleke

Mr. Adebisi Abiodun Adeleke

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AAAdebisi Abiodun Adeleke
Adebisi Abiodun Adeleke
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
KAKafilat Agbaje
Kafilat Agbaje
OOOluwabukunmi Olajubutu
Oluwabukunmi Olajubutu
SASimeon K. Adesina
Simeon K. Adesina
Colorectal cancer (CRC) is ranked as the third most lethal of all cancers in the USA, following prostate and lung malignancy in men, and breast and lung malignancy in women, respectively. The risk factors for developing colorectal cancer fall into two categories: modifiable risk factors (obesity and physical inactivity, diet, smoking, alcohol, medications, diabetes, and insulin resistance) and non-modifiable risk factors (race and ethnicity, sex, age, and inflammatory bowel disease). The standard therapeutic approaches to the treatment of colorectal cancer have led to a reduction in the burden of colorectal cancer in the USA, with national statistics revealing a reduction in both the incidence and death rates. At the same time, five-year survival rates have also greatly improved. However, associated with these standard treatments are complications, which have become a burden (physical and emotional, financial, and economic burdens, and disability-adjusted life years), affecting the quality of life of CRC patients. This paper discusses the standard therapeutic approaches to managing colorectal cancer, the associated complications, and their management. In addition, a summary of the newly introduced therapeutic approaches for treating CRC, reported improvement in effectiveness over existing strategies and corresponding reduction in therapeutic complications will be discussed.

3 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
AAAdebisi Abiodun Adeleke
Adebisi Abiodun Adeleke
SASimeon K. Adesina
Simeon K. Adesina
KAKafilat Agbaje
Kafilat Agbaje
OOOluwabukunmi Olajubutu
Oluwabukunmi Olajubutu
Colorectal cancer (CRC) is ranked as the third most lethal of all cancers in the USA, following prostate and lung malignancy in men, and breast and lung malignancy in women respectively. The risk factors for developing colorectal cancer fall into 2 categories: modifiable risk factors (obesity and physical inactivity, diet, smoking, alcohol, medications, diabetes, and insulin resistance) and non-modifiable risk factors (race and ethnicity, sex, age, and inflammatory bowel disease). The standard therapeutic approaches to the treatment of colorectal cancer have led to a reduction in the burden of colorectal cancer in the USA, with national statistics revealing a reduction in both the incidence and death rates. At the same time, 5-year survival rates have also greatly improved. However, associated with these standard treatments are complications, which have become a burden (physical and emotional, financial, and economic burdens, and disability-adjusted life years), affecting the quality of life of CRC patients. This paper discusses the standard therapeutic approaches to managing colorectal cancer, the associated complications and their management. In addition, a summary of the newly introduced therapeutic approaches for treating CRC, reported improvement in effectiveness over existing strategies and corresponding reduction in therapeutic complications will be discussed.

5 May 2026 in European Journal of Biology
Verified
Journal Article
Closed access
DBDoofan Bur
Doofan Bur
IAIsrael Akinrotimi Akinola
Israel Akinrotimi Akinola
AAAdebisi Abiodun Adeleke
Adebisi Abiodun Adeleke
EEEmmanuel Kennedy Ezika
Emmanuel Kennedy Ezika
KEKelechi Purity Ezennubia
Kelechi Purity Ezennubia
ARAdekunle Rowaiye
Adekunle Rowaiye
To disassemble the mechanisms of action of antipathogenic probiotics from Lactobacillus and Bifidobacterium genera, specifically competitive exclusion, bacteriocin production, short-chain fatty acid release, and immune modulation, to inform the development of microbiome-sparing compounds for multidrug-resistant infections. We conducted a systematic literature search across PubMed, Web of Science, Medline, and Google Scholar, identifying 104 pertinent articles published between 2018 and 2025. These studies were analysed to elucidate the antimicrobial mechanisms of probiotic-derived molecules and their potential for drug development. The analysis of 104 articles revealed that probiotic-derived molecules, including bacteriocins and short-chain fatty acids, create an adaptive anti-pathogen toolkit through competitive exclusion and immune modulation. These mechanisms effectively target MDR pathogens. However, translation to clinical settings remains complex due to inconsistent trial results and highly strain-specific therapeutic effects, underscoring the need for careful validation. Understanding the structural determinants of probiotic-derived molecules could enable the rational design of microbiome-compatible antivirulence drugs and bacteriocin mimetics that neutralise pathogens without harming the commensal microbiota. Harnessing these insights may extend the lifespan of existing antibiotics while advancing sustainable, ecosystem-friendly therapeutics for the post-antibiotic era.